We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $2.04B
1-Year Est. Return 94.26%
This Fund
S&P 500
This Quarter Est. Return
+21.35%
1 Year Est. Return
+94.26%
3 Year Est. Return
+310.51%
5 Year Est. Return
+306.13%
10 Year Est. Return
+3,783.92%
AUM
$2.04B
AUM Growth
+$120M
Cap. Flow
-$149M
Cap. Flow %
-7.33%
Top 10 Hldgs %
47.27%
Holding
257
New
21
Increased
32
Reduced
47
Closed
104

Top Buys

Rank Stock Value
1
U icon
Unity
U
+$16.4M
2
TRAX
First Tracks Biotherapeutics
TRAX
+$14M
3
SE icon
Sea Limited
SE
+$11.9M
4
NU icon
Nu Holdings
NU
+$10.1M
5
GOSS icon
Gossamer Bio
GOSS
+$9.54M

Top Sells

Rank Stock Value
1
ASTH icon
Astrana Health
ASTH
+$17.6M
2
LLY icon
Eli Lilly
LLY
+$15.3M
3
GXO icon
GXO Logistics
GXO
+$14.8M
4
FOLD
Amicus Therapeutics
FOLD
+$11.2M
5
APLS
Apellis Pharmaceuticals
APLS
+$10.1M

Sector Composition

Rank Sector Weight
1 Miscellaneous 48.9%
2 Healthcare 24.5%
3 Financials 7.3%
4 Consumer Discretionary 7.28%
5 Technology 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMT icon
226
Sagimet Biosciences
SGMT
$675M
– –
-126,349
Closed -$660K
SPCE icon
227
Virgin Galactic
SPCE
$449M
– –
-280,160
Closed -$681K
SRFM icon
228
Surf Air Mobility
SRFM
$76M
– –
-202,971
Closed -$233K
SRI icon
229
Stoneridge
SRI
$206M
– –
-90,000
Closed -$435K
SRRK icon
230
PUT
Scholar Rock
SRRK
$6.65B
– –
-16,200
Closed -$796K
SRZN icon
231
Surrozen
SRZN
$235M
– –
-33,000
Closed -$961K
STGW icon
232
Stagwell
STGW
$2.08B
– –
-305,000
Closed -$1.92M
TAYD icon
233
Taylor Devices
TAYD
$195M
– –
-7,000
Closed -$399K
TBPH icon
234
Theravance Biopharma
TBPH
$886M
– –
-250,000
Closed -$4.06M
TSLA icon
235
PUT
Tesla
TSLA
$1.45T
– –
-110,000
Closed -$40.9M
TWIN icon
236
Twin Disc
TWIN
$359M
– –
-31,967
Closed -$482K
VERI icon
237
Veritone
VERI
$86.2M
– –
-191,517
Closed -$377K
VKTX icon
238
Viking Therapeutics
VKTX
$3.81B
– –
-130,000
Closed -$4.2M
VTVT icon
239
vTv Therapeutics
VTVT
$132M
– –
-16,000
Closed -$635K
XHR
240
Xenia Hotels & Resorts
XHR
$1.63B
– –
-55,000
Closed -$816K
ZURA icon
241
Zura Bio
ZURA
$547M
– –
-110,000
Closed -$655K
ANRO icon
242
Alto Neuroscience
ANRO
$1.34B
– –
-40,000
Closed -$899K
KYTX icon
243
Kyverna Therapeutics
KYTX
$472M
– –
-85,000
Closed -$734K
UMAC icon
244
Unusual Machines
UMAC
$1.21B
– –
-55,000
Closed -$682K
AIFC
245
AI Financial Corp
AIFC
$71.2M
– –
-410,000
Closed -$455K
CTNM
246
Contineum Therapeutics
CTNM
$570M
– –
-55,000
Closed -$718K
PCSC
247
DELISTED
Perceptive Capital Solutions
PCSC
– –
-561,923
Closed -$6.16M
LGCY
248
Legacy Education Inc
LGCY
$130M
– –
-40,000
Closed -$501K
CLYM
249
Climb Bio
CLYM
$864M
– –
-90,000
Closed -$617K
JFB
250
DELISTED
JFB Construction Holdings
JFB
– –
-38,000
Closed -$233K
7 8 9
10
11

Similar funds

SFI
Siemens Fonds Invest Munich, Germany $2.04B AUM 40.78% 1-Year Est. Return
UF
Univest Financial Souderton, Pennsylvania $2.04B AUM 33.06% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
C
Certuity North Palm Beach, Florida $2.03B AUM 88.59% 1-Year Est. Return
EF
Evanson Financial Mclean, Virginia $2.04B AUM
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return

683 Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, 683 Capital Management held 257 positions worth $2.04B, up 6.3% from $1.92B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

683 Capital Management withdrew a net $149M in Q2 2026, closing 104 positions and reducing 47 holdings. Its most notable exit was Eli Lilly, an estimated $15.3M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, up from 47% a quarter earlier, followed by Healthcare and Financials.

Against the trend, 683 Capital Management opened a new position in Unity worth $17.6M.

  • 683 Capital Management's largest Q2 2026 buy was Unity: 615,000 shares worth $17.6M.
  • 683 Capital Management added most to Gossamer Bio in Q2 2026, an estimated $9.54M increase.
  • 683 Capital Management's biggest Q2 2026 reduction was Astrana Health, cutting an estimated $17.6M.
  • 683 Capital Management fully exited Eli Lilly in Q2 2026, selling an estimated $15.3M.
  • 683 Capital Management's ten largest holdings make up 47% of its $2.04B portfolio in Q2 2026.
  • 683 Capital Management opened 21 new positions and closed 104 in Q2 2026.
  • 683 Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.04B.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.